Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade D 74.5 -0.39% -0.29
BPMC closed up 1.59 percent on Thursday, October 17, 2019, on 58 percent of normal volume.

Earnings due: Oct 28

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical BPMC trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.39%
Crossed Above 20 DMA Bullish -0.39%
20 DMA Resistance Bearish 1.20%
Spinning Top Other 1.20%
MACD Bullish Signal Line Cross Bullish 1.13%
Spinning Top Other 1.13%
NR7 Range Contraction 3.56%
NR7-2 Range Contraction 3.56%
Oversold Stochastic Weakness 3.56%
Death Cross Bearish 3.54%

Older signals for BPMC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 102.98
52 Week Low 44.58
Average Volume 393,876
200-Day Moving Average 80.6818
50-Day Moving Average 77.6508
20-Day Moving Average 74.3625
10-Day Moving Average 73.083
Average True Range 2.8129
ADX 29.54
+DI 16.9543
-DI 22.0818
Chandelier Exit (Long, 3 ATRs ) 72.9213
Chandelier Exit (Short, 3 ATRs ) 78.2487
Upper Bollinger Band 79.5542
Lower Bollinger Band 69.1708
Percent B (%b) 0.54
BandWidth 13.963221
MACD Line -1.4248
MACD Signal Line -1.8287
MACD Histogram 0.4039
Fundamentals Value
Market Cap 2.93 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -23.97
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.91
Resistance 3 (R3) 77.87 76.79 77.39
Resistance 2 (R2) 76.79 76.00 76.81 77.22
Resistance 1 (R1) 75.79 75.50 76.29 75.83 77.04
Pivot Point 74.71 74.71 74.96 74.73 74.71
Support 1 (S1) 73.71 73.92 74.21 73.75 72.54
Support 2 (S2) 72.63 73.42 72.65 72.36
Support 3 (S3) 71.63 72.63 72.19
Support 4 (S4) 71.67